ArticlePolymers2024
Computational Simulation Study-Based Formulation Development and Characterization of MethylprednisoloneLoaded Nanoparticles Containing Chitosan and Pectin to Treat Nocturnal Asthma.
Article in Polymers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nocturnal asthma (NA) is a high-prevalence disease that causes severe respiratory issues, leading to death from early midnight to early morning. In this research, nanoparticulate drug delivery system of methylprednisolone (MP) was developed using chitosan (CH) and pectin (PEC). MP is a synthetic corticosteroid medication widely used for its potent anti-inflammatory activity. Computational simulation study (AI-based blend analysis algorithm) was used to identify a better-mixing polymer with MP. MP nanoparticles were formulated by the ionic gelation method with the combination of CH and PEC. To modify the drug release properties, the formed beads were coated with chitosan succinate (CSSC). The morphological characteristics of the beads were determined by SEM analysis. The X-ray radiographic imaging study was used to observe the intactness of MP beads. Histopathological studies were also carried out to find out the toxicity of the beads in the organs of rats. Pectin and chitosan polymers were selected based on the computational simulation study. SEM analysis revealed that the beads had a spherical shape with a rough outer surface. CSSC-coated beads achieved sustained drug release for up to 24 h. X-ray imaging demonstrated the stability of the beads in acidic pH conditions. In vivo pharmacokinetic studies showed that CSSC-coated beads were more stable in the gastrointestinal tract (GIT) than PEC-CH beads and the pure drug. Histological evaluation confirmed that the beads are nontoxic and safe for use in rats. Based on the findings, it was concluded that CSSC-coated beads of MP exhibited superior release properties, making them suitable for a chronomodulated drug delivery system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.